Evofem terminates merger with Aditxt due to Aditxt's failure to make Initial Parent Equity Investment

Aditxt, Inc.

Evofem Biosciences terminated Merger Agreement effective April 26, 2024.
Termination due to Aditxt's failure to provide the Initial Parent Equity Investment as defined in the agreement.
The Merger would have resulted in Evofem becoming a wholly owned subsidiary of Aditxt.
Aditxt had previously disclosed the Merger Agreement in December 2023.
The termination is immediate per Evofem's notice.

item 1.02

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aditxt, Inc. terminated Agreement and Plan of Merger with Evofem Biosciences, Inc. (effective 2024-04-26).

Action: termination
Agreement: merger
Counterparty: Evofem Biosciences, Inc.
Effective: 2024-04-26

Exact text from the filing

On April 26, 2024, the Company received notice from Evofem that Evofem was exercising its right to terminate the Merger Agreement effective immediately as a result of the Company’s failure to provide the Initial Parent Equity Investment (as defined in the Merger Agreement, as amended).

View on SEC.gov

292 material agreements filed in the last 30 days. Browse all material agreements →

Aditxt, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-039238

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.